Rapamune
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved September 1999
Treatment for: To prevent organ rejection in patients receiving renal transplants
Areas: Immunology/Infectious Diseases
Possible similar drugs: Rapamune
| General Information | Mechanism of Action |
General Information
Other Useful Resources
An oral solution of sirolimus to act as a prophylaxis to prevent organ rejection in patients that are receiving liver transplants.
Mechanism of Action
Oral solution of sirolimus, 1 mg/ml.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
